1. Home
  2. TSLX vs NVAX Comparison

TSLX vs NVAX Comparison

Compare TSLX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

N/A

Current Price

$18.06

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

N/A

Current Price

$10.64

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
NVAX
Founded
2010
1987
Country
United States
United States
Employees
N/A
749
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
TSLX
NVAX
Price
$18.06
$10.64
Analyst Decision
Buy
Buy
Analyst Count
11
9
Target Price
★ $19.77
$14.00
AVG Volume (30 Days)
363.2K
★ 4.4M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 9.82%
N/A
EPS Growth
N/A
★ 309.76
EPS
★ 0.15
N/A
Revenue
N/A
★ $1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.99
N/A
P/E Ratio
$122.30
★ N/A
Revenue Growth
N/A
★ 64.69
52 Week Low
$16.04
$6.20
52 Week High
$23.19
$11.85

Technical Indicators

Market Signals
Indicator
TSLX
NVAX
Relative Strength Index (RSI) 46.69 66.82
Support Level $17.20 $8.42
Resistance Level $18.59 $10.85
Average True Range (ATR) 0.33 0.51
MACD -0.00 0.03
Stochastic Oscillator 34.95 85.83

Price Performance

Historical Comparison
TSLX
NVAX

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: